Carregant...
Exploiting defects in homologous recombination repair for metastatic, castration-resistant prostate cancer
The PROfound trial highlights that there is a benefit in testing genes involved in homologous recombination (HR) and forms the rationale for testing in all patients with metastatic, castration-resistant prostate cancer (mCRPC). This trial also demostrates that olaparib improves progression free surv...
Guardat en:
| Publicat a: | Cancer Biol Ther |
|---|---|
| Autors principals: | , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Taylor & Francis
2020
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7583699/ https://ncbi.nlm.nih.gov/pubmed/32844710 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15384047.2020.1809913 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|